Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for MDGEF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
December 31, 2019 91.85M
September 30, 2019 93.51M
June 30, 2019 103.89M
March 31, 2019 114.70M
December 31, 2018 118.03M
September 30, 2018 121.89M
June 30, 2018 127.72M
March 31, 2018 101.84M
December 31, 2017 103.47M
September 30, 2017 105.29M
June 30, 2017 103.06M
March 31, 2017 80.19M
December 31, 2016 82.89M
September 30, 2016 92.21M
June 30, 2016 97.29M
March 31, 2016 100.41M
December 31, 2015 97.75M
September 30, 2015 102.44M
June 30, 2015 59.38M
March 31, 2015 49.25M
December 31, 2014 59.38M
September 30, 2014 62.44M
June 30, 2014 51.18M
March 31, 2014 52.37M
December 31, 2013 49.99M
Date Value
September 30, 2013 52.62M
June 30, 2013 53.28M
March 31, 2013 52.65M
December 31, 2012 58.29M
September 30, 2012 58.57M
June 30, 2012 60.91M
March 31, 2012 60.73M
December 31, 2011 62.22M
September 30, 2011 73.71M
June 30, 2011 79.26M
March 31, 2011 81.32M
September 30, 2010 67.98M
June 30, 2010 68.18M
March 31, 2010 69.76M
December 31, 2009 74.42M
September 30, 2009 75.23M
June 30, 2009 85.61M
March 31, 2009 85.57M
December 31, 2008 90.22M
September 30, 2008 106.81M
June 30, 2008 133.16M
March 31, 2008 144.92M
December 31, 2007 150.73M
September 30, 2007 163.17M
June 30, 2007 146.11M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
InflaRx NV 167.13M
BioNTech SE 20.30B
Immatics NV 456.89M
Arrowhead Pharmaceuticals, Inc. 465.53M
Oncolytics Biotech, Inc. -6.167M